Benign prostatic hyperplasia (BPH) is one of the most common disease and major cause of morbidity in elderly men which may lead to bladder outflow obstruction and lower urinary tract symptoms (LUTS). Although sex steroid hormones play fundamental roles in prostate growth, their clinical significance is not completely clear. In the present study we assessed whether serum hormones levels as markers of prostate disease. This study includes (40) patients with benign prostatic hypertrophy and (40) control group with age rang (41-79) and (42-71) years respectively. The following biochemical investigations have been studied: Testosterone, Estradiol (E2), and Prostatic Specific Antigen (PSA) levels using ELISA method which correlated with the disease. Also body mass index (BMI), the prostate size by digital rectal examination (DRE), flow rate, and American Urology Association Symptoms Index (AUASI), of the patients which correlate hormones levels with age. The testosterone concentrations were significantly lower in patients with BPH than control group (p?0.05), while the Estradiol and PSA concentrations were significantly higher in patients with BPH than control group (p?0.05). The net result is a significant decrease in the T/E2 ratio allowing the imbalance between androgens and estrogen regulation of prostate growth to shift towards estrogen dominance. It has been proposed that increased estrogenic stimulation of the prostate in the aging male may lead to reactivation of growth and subsequent hyperplasia transformation